This is an exciting era in pharmacology, and cardiovascular pharmacology provides a good example of this excitement. Substantial advances have been made in our understanding of cardiovascular physiology and in the pathophysiology of the major diseases with which we are dealing: heart failure, hypertension, and coronary artery disease. The methods of diagnosis of cardiovascular diseases and of evaluating the efficacy of pharmacologic therapy have progressed also. Better patient care and innovative cardiovascular pharmacology have evolved because of these advances.
Not many years ago, if an investigator wanted to study an antiarrhythmic drug, he administered the drug to a hospitalized patient with an arrhythmia and did an ECG every half hour. Now we have coronary care units and electronic monitoring, including Holter tapes to monitor patients outside of the hospital during their daily activities. As a result, we can get better data more rapidly on the effect of new drugs. These
Hayes AH. Advances in Cardiovascular Pharmacology. JAMA. 1982;248(5):537–543. doi:10.1001/jama.1982.03330050021010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: